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S256 Poster Session Itransplantation (OHT) followed by autologous hematopoietic stem
cell transplantation (ASCT).
Age at AL presentation was 63, 62 and 44 years in 2 females and 1
male. Diagnosis of cardiac AL was established via endomyocardial
biopsy, Congo red staining and immunohistochemistry. All had
end stage heart failure with New York Heart Association class 4
symptoms and developed cardiogenic shock requiring intra-aortic
balloon pump support as a bridge to OHT. All were considered un-
suitable for ASCT.
ASCT was performed 13, 16 and 13 months after OHT (table-1).
All 3 patients were on tacrolimus and prednisone at the time of stem
cell mobilization and hematopoietic transplant; two patients were
also receiving mycophenolate mofetil and valganciclovir. We col-
lected 6.1 and 6.2 x 106/kg CD-34+ cells in 2 days with filgrastim
(5 ug/kg, twice, daily) and plerixafor (16 mg/kg based on day- 4
CD-34+ counts) in two subjects. The third initially failed to mobilize
but 4.3x106/kg CD-34+ cells were subsequently obtained when she
(patient #2) was remobilized with filgrastim and plerixafor 4 weeks
after stopping mycophenolate mofetil. The creatinine clearance at
the time of high-dose chemotherapy was 36, 30 and 43 ml/minute.
All 3 patients received renal adjusted dose of melphalan at 140mg/
m2.Mycophenolatemofetil andValganciclovir were withheld during
neutropenia until engraftment. Time to engraftment for neutrophils
(ANC of.500/uL x3 days) was 13, 11 and 14 days. Platelets engraft-
ment (untransfused.20 x 109 for 3 consecutive days) occurred in 14,
13 and 16 days. No patients received post-transplant filgrastim. Pa-
tients were hospitalized for 17, 18 and 18 days. Renal function re-
mained stable during ASCT and non-hematological toxicity was
limited to grade I-II apart from one grade III oral mucositis and co-
litis. One patient achieved hematologic complete remission (pa-
tient#2) while 2 patients had partial response following ASCT.
Post OHT and ASCT all patients are alive and well at follow-up
of 14, 26 and 30 months from OHT.
OHT should be considered in select patients with dominant car-
diac involvement and advanced heart failure to allow subsequent
ASCT and improve survival.
Table. Orthotopic heart transplantation (OHT) followed by
ASCT
Time toAge/
SexTime to
AL diagnosis
(months)Organ
involvementInitial
treatmentTime to
OHT*
(months)ASCT
post OHT
(monthsSurvival
(months)63/F 12 Heart,
kidney,
PNLenalidomide/
dexamethasone7 13 32+62/F 24 Heart,
Kidney,
PNMelphalan/
dexamethasone5 16 26+44/M 12 Heart,
Kidney,
tongueLenalidomide/
dexamethasone4 13 16+*Time to OHT from onset of heart failure symptoms, PN 5 peripheral
nerve, F 5 female, M 5 male140
AUTOLOGOUS STEM CELL TRANSPLANT FOR A PATIENT WITH RELAPS-
ING-REMITTING MULTIPLE SCLEROSIS
Ibrahim, K.A. St Vincent’s Hospital, Sydney, NSW, Australia
Objective: To highlight the use of autologous bone marrow trans-
plantation (BMT) as an option for patients with relapsing-remitting
Multiple Sclerosis.
Clinical Features: A 43-year-old female was diagnosed with Multi-
ple Sclerosis (MS) in 2002. She presented with progressive leg weak-
ness resulting in some impairment of mobility and urinary retention
requiring self-catheterisation. She was commenced on glatiramer ac-
etate with little response. In July 2003 her therapy was changed to in-
terferon from which she had profound side effects. She was switched
back to glatiramer but experienced 3-4 relapses per year. Whilst onglatiramer she became pregnant in 2006. Her MS control was very
good during pregnancy. Nine months after delivery her disease re-
lapsed with further worsening of the right leg weakness and blurring
of the vision in the right eye. In 2009 she underwent treatment with
natalizumab once a month. Initially she had some response to nata-
lizumab but after a year of therapy her disease continued to progress
both clinically and radiologically.
Interventions, Case Progress and Outcome: She was then re-
ferred to the BMT unit for considering autologous stem cell trans-
plant (ASCT) for her condition. In December 2010 she underwent
ASCT with conditioning chemotherapy regimen BEAM (carmus-
tine, etoposide, cytarabine and melphalan) with antithymocyte glob-
ulin (ATG) 20mg/kg for 2 doses. Her transplant course was
complicated by septicaemia with Strep species. Six months after
the ASCT she recovered completely from the procedure and a prog-
ressMRI scan in April 2011 showed significant reduction of the CNS
inflammation and MS lesions. Furthermore she reported significant
improvement in mobility and bladder function.
Conclusions: The use of autologous BMT can be considered as an
option for patients with relapsing-remitting MS who have pro-
gressed on different immunotherapies. Careful selection of patients
with good performance status is crucial as this procedure carries
a 1% mortality risk.141
MULTI-DOSE PHARMACOKINETIC STUDY OF PLERIXAFOR IN A MOR-
BIDLY OBESE PATIENT WITH MULTIPLE MYELOMA AND DIALYSIS-DE-
PENDENT RENAL IMPAIRMENT
Vozniak, J.M.1, Davis, L.E.2, Stadtmauer, E.A.3 1Hospital of the Uni-
versity of Pennsylvania, Philadelphia, PA; 2College of Pharmacy, Univer-
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Plerixafor is a CXCR4 antagonist approved formobilization of he-
matopoietic stem cells (HSC) in patients undergoing an autologous
stem cell transplant (AuSCT). Renal dose adjustments are recom-
mended but no data is available for dosing plerixafor in dialysis-de-
pendent patients. To our knowledge no literature describes the
pharmacokinetic (PK) characteristics of plerixafor in patients with
dialysis-dependent renal impairment.
We present a 44-year old morbidly obese (182kg; BMI 61.1) female
with IgGmultiplemyeloma with dialysis-dependent renal impairment
that underwent mobilization with plerixafor and filgrastim. Filgrastim
10mcg/kg/day was initiated 3 days before HSC collection 1. Prior to
plerixafor dosing the patient’s CD34+ 5 9 cells/microL. Plerixafor
started the evening of day 3 andHSCcollection 1 began 11 hours later.
Overall, 3 plerixafor doses were administered. HSC collection 2 began
16 hours after dose 2 and HSC collection 3 began 11 hours following
dose 3. Dialysis (HD) occurred after HSC collections 1 and 3.
Multi-dose PK analysis was conducted (WinNonlin). Data follow-
ing the first dose off HDwere fit to a 2-compartment model with Cl/
F: 3.56 L/hr, V/F: 56.6 L, distribution T1/2: 0.6 hr, and elimination
T1/2: 11 hr. The table summarizes non-compartmental analysis of
each parameter from each day.
Table. Plerixafor Pharmacokinetics by Dose
Apparent ApparentDose
NumberDose
(mg)Tmax
(hr)Cmax
(ng/mL)AUC 0-inf
(ng* hr/mL)Clearance
(L/hr)
Off HDClearance
(L/hr)
On HDHD (4 hr)
Schedule1 27 0.75 602 6406 3.57 10.7 Start 16.4 hr
post-dose2 27 1 665 10919 2.47 – –3 40 1 814 13463 2.16 8.0 Start 17.5 hr
post-doseinf 5 infinity; HD 5 dialysis
HSC collection 1, 2 and 3 yielded 2.2, 2.4 and 3.9 x 106 CD34+
cells/kg, respectively for a total of 8.5 x106 CD34+ cells/kg. Side-
